BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11410506)

  • 1. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization.
    Stadler WM; Steinberg G; Yang X; Hagos F; Turner C; Olopade OI
    Clin Cancer Res; 2001 Jun; 7(6):1676-82. PubMed ID: 11410506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma.
    Hopman AH; Kamps MA; Speel EJ; Schapers RF; Sauter G; Ramaekers FC
    Am J Pathol; 2002 Oct; 161(4):1119-25. PubMed ID: 12368185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
    Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
    Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
    Stadler WM; Olopade OI
    Urol Res; 1996; 24(4):239-44. PubMed ID: 8873383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
    Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
    Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients.
    Obermann EC; Meyer S; Hellge D; Zaak D; Filbeck T; Stoehr R; Hofstaedter F; Hartmann A; Knuechel R
    Oncol Rep; 2004 Apr; 11(4):745-51. PubMed ID: 15010867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters.
    Gallucci M; Guadagni F; Marzano R; Leonardo C; Merola R; Sentinelli S; Ruggeri EM; Cantiani R; Sperduti I; Lopez Fde L; Cianciulli AM
    J Clin Pathol; 2005 Apr; 58(4):367-71. PubMed ID: 15790699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer.
    Sauter G; Moch H; Carroll P; Kerschmann R; Mihatsch MJ; Waldman FM
    Int J Cancer; 1995 Apr; 64(2):99-103. PubMed ID: 7615360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
    Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
    Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study.
    Placer J; Espinet B; Salido M; Solé F; Gelabert-Mas A
    Urology; 2005 May; 65(5):913-8. PubMed ID: 15882723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
    Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
    Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.
    Jagasia AA; Block JA; Qureshi A; Diaz MO; Nobori T; Gitelis S; Iyer AP
    Cancer Lett; 1996 Jul; 105(1):91-103. PubMed ID: 8689637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
    Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
    Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
    Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
    Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.
    Stadler WM; Sherman J; Bohlander SK; Roulston D; Dreyling M; Rukstalis D; Olopade OI
    Cancer Res; 1994 Apr; 54(8):2060-3. PubMed ID: 7513608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
    Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
    Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
    Ohta M; Berd D; Shimizu M; Nagai H; Cotticelli M-G ; Mastrangelo M; Shields JA; Shields CL; Croce CM; Huebner K
    Int J Cancer; 1996 Mar; 65(6):762-7. PubMed ID: 8631588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
    Faderl S; Estrov Z; Kantarjian HM; Thomas D; Cortes J; Manshouri T; Chan CC; Hays KJ; Pierce S; Albitar M
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):159-63. PubMed ID: 10641574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased p16 levels correlate with pRb alterations in human urothelial cells.
    Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
    Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.